Shire and AbbVie Discuss Possible Deal - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Shire and AbbVie Discuss Possible Deal


In a July 14 statement, Shire reported that the company had requested and received a revised proposal from AbbVie on July 13 for cash and AbbVie shares, with an indicative value of 53.20 British pounds per Shire share, based on share prices of July 11.

Under the revised proposal, Shire shareholders would own approximately 25% of the combined new AbbVie. The new proposal is valued at $53 billion (31 billion pounds) by Reuters.

“The Board of Shire has indicated to AbbVie that it would be willing to recommend an offer at the level of the Revised Proposal to Shire shareholders subject to satisfactory resolution of the other terms of the offer. Accordingly, the Board is in detailed discussions with AbbVie in relation to these terms,” the statement reports.

Shire reports that the revised proposal is subject to the pre-conditions set by AbbVie on July 8, 2014 including due diligence and the recommendation of the Board of Shire and warned that “There can be no certainty that any firm offer will be made.”

Sources:
Shire
Reuters

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here